叶酸聚乙烯亚胺多聚物将基因转移到三阴性乳腺癌细胞中

Q3 Pharmacology, Toxicology and Pharmaceutics
Devrim DEMİR DORA
{"title":"叶酸聚乙烯亚胺多聚物将基因转移到三阴性乳腺癌细胞中","authors":"Devrim DEMİR DORA","doi":"10.55262/fabadeczacilik.1347084","DOIUrl":null,"url":null,"abstract":"Triple negative breast cancer (TNBC) is the most aggressive subtype of breast cancer and lacks hormonal and growth factor receptors commonly expressed by other types of breast cancer making it difficult to treat by conventional treatments. Although gene therapy might be a therapeutic option, delivery of genes into TNBC cells is still an obstacle. In this study, it was aimed to overcome this obstacle by folic acid (FA) conjugated polyplex formulations to targeting the folate receptor which has been reported to be overexpressed in TNBC cells. Non-covalent complexes of FA and LPEI polyplexes (FA-polyplexes) were prepared at six different ratios. After characterization studies, cytotoxicity and transfection ability were evaluated. Conjugation of FA by increasing amounts of LPEI polyplexes, increased the size from 204.1 to 469.8 nm. Their PDI values were between 0.31-0.51, and zeta potentials were positive. After treatment with polyplex formulations, cell viability was decreased significantly starting from 3:1(w/w) polymer:pDNA ratio and from 3:3:1 (w/w)FA:polyplex ratio. Cell viability decreased below 70% above the 5:1 (w/w) polymer:pDNA ratio. Addition of folic acid to polyplex formulations reversed the cytotoxicity of P3, P4 and P5 formulations. Although LV-RFP pDNA was delivered successfully into 4T1 cells by all formulations, fluorescent microscope images showed that, the optimal formulations were FA-P3 and FA-P4. This gene delivery system, generated by non-covalent conjugation of folic acid to polyplexes, increased the uptake and decreased the cytotoxicity of LPEI polyplexes. Non-covalent complexes of folic acid-LPEI polyplexes represent promising delivery systems in gene therapy, directed against cancer cells expressing folate receptors.","PeriodicalId":36004,"journal":{"name":"Fabad Journal of Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Üçlü negatif meme kanseri hücrelerine folik asit polietilenimin polipleksleri ile gen aktarımı\",\"authors\":\"Devrim DEMİR DORA\",\"doi\":\"10.55262/fabadeczacilik.1347084\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Triple negative breast cancer (TNBC) is the most aggressive subtype of breast cancer and lacks hormonal and growth factor receptors commonly expressed by other types of breast cancer making it difficult to treat by conventional treatments. Although gene therapy might be a therapeutic option, delivery of genes into TNBC cells is still an obstacle. In this study, it was aimed to overcome this obstacle by folic acid (FA) conjugated polyplex formulations to targeting the folate receptor which has been reported to be overexpressed in TNBC cells. Non-covalent complexes of FA and LPEI polyplexes (FA-polyplexes) were prepared at six different ratios. After characterization studies, cytotoxicity and transfection ability were evaluated. Conjugation of FA by increasing amounts of LPEI polyplexes, increased the size from 204.1 to 469.8 nm. Their PDI values were between 0.31-0.51, and zeta potentials were positive. After treatment with polyplex formulations, cell viability was decreased significantly starting from 3:1(w/w) polymer:pDNA ratio and from 3:3:1 (w/w)FA:polyplex ratio. Cell viability decreased below 70% above the 5:1 (w/w) polymer:pDNA ratio. Addition of folic acid to polyplex formulations reversed the cytotoxicity of P3, P4 and P5 formulations. Although LV-RFP pDNA was delivered successfully into 4T1 cells by all formulations, fluorescent microscope images showed that, the optimal formulations were FA-P3 and FA-P4. This gene delivery system, generated by non-covalent conjugation of folic acid to polyplexes, increased the uptake and decreased the cytotoxicity of LPEI polyplexes. Non-covalent complexes of folic acid-LPEI polyplexes represent promising delivery systems in gene therapy, directed against cancer cells expressing folate receptors.\",\"PeriodicalId\":36004,\"journal\":{\"name\":\"Fabad Journal of Pharmaceutical Sciences\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Fabad Journal of Pharmaceutical Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.55262/fabadeczacilik.1347084\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Fabad Journal of Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.55262/fabadeczacilik.1347084","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

摘要

三阴性乳腺癌(TNBC)是乳腺癌中最具侵袭性的亚型,缺乏其他类型乳腺癌常见的激素和生长因子受体,因此难以通过常规治疗进行治疗。虽然基因治疗可能是一种治疗选择,但将基因传递到TNBC细胞中仍然是一个障碍。在这项研究中,它的目的是克服这一障碍,叶酸(FA)共轭复合制剂靶向叶酸受体,已报道过表达在TNBC细胞。以6种不同的比例制备了FA-polyplexes (FA-polyplexes)。经鉴定后,对细胞毒性和转染能力进行评价。通过增加LPEI多聚物的量来偶联FA,使尺寸从204.1 nm增加到469.8 nm。PDI值在0.31 ~ 0.51之间,zeta电位呈阳性。复合物处理后,从3:1(w/w)聚合物:pDNA比例和3:3:1 (w/w)FA:复合物比例开始,细胞活力显著降低。超过5:1 (w/w)的聚合物:pDNA比,细胞活力下降到70%以下。在复合制剂中添加叶酸可逆转P3、P4和P5制剂的细胞毒性。虽然所有配方均能成功将LV-RFP pDNA传递到4T1细胞中,但荧光显微镜图像显示,最佳配方为FA-P3和FA-P4。这种基因传递系统是由叶酸与多聚物非共价偶联产生的,增加了LPEI多聚物的摄取并降低了细胞毒性。叶酸- lpei复合物的非共价复合物在基因治疗中代表了有前途的递送系统,直接针对表达叶酸受体的癌细胞。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Üçlü negatif meme kanseri hücrelerine folik asit polietilenimin polipleksleri ile gen aktarımı
Triple negative breast cancer (TNBC) is the most aggressive subtype of breast cancer and lacks hormonal and growth factor receptors commonly expressed by other types of breast cancer making it difficult to treat by conventional treatments. Although gene therapy might be a therapeutic option, delivery of genes into TNBC cells is still an obstacle. In this study, it was aimed to overcome this obstacle by folic acid (FA) conjugated polyplex formulations to targeting the folate receptor which has been reported to be overexpressed in TNBC cells. Non-covalent complexes of FA and LPEI polyplexes (FA-polyplexes) were prepared at six different ratios. After characterization studies, cytotoxicity and transfection ability were evaluated. Conjugation of FA by increasing amounts of LPEI polyplexes, increased the size from 204.1 to 469.8 nm. Their PDI values were between 0.31-0.51, and zeta potentials were positive. After treatment with polyplex formulations, cell viability was decreased significantly starting from 3:1(w/w) polymer:pDNA ratio and from 3:3:1 (w/w)FA:polyplex ratio. Cell viability decreased below 70% above the 5:1 (w/w) polymer:pDNA ratio. Addition of folic acid to polyplex formulations reversed the cytotoxicity of P3, P4 and P5 formulations. Although LV-RFP pDNA was delivered successfully into 4T1 cells by all formulations, fluorescent microscope images showed that, the optimal formulations were FA-P3 and FA-P4. This gene delivery system, generated by non-covalent conjugation of folic acid to polyplexes, increased the uptake and decreased the cytotoxicity of LPEI polyplexes. Non-covalent complexes of folic acid-LPEI polyplexes represent promising delivery systems in gene therapy, directed against cancer cells expressing folate receptors.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Fabad Journal of Pharmaceutical Sciences
Fabad Journal of Pharmaceutical Sciences Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
0.80
自引率
0.00%
发文量
12
期刊介绍: The FABAD Journal of Pharmaceutical Sciences is published triannually by the Society of Pharmaceutical Sciences of Ankara (FABAD). All expressions of opinion and statements of supposed facts appearing in articles and/or advertisiments carried in this journal are published on the responsibility of the author and/or advertiser, anda re not to be regarded those of the Society of Pharmaceutical Sciences of Ankara. The manuscript submitted to the Journal has the requirement of not being published previously and has not been submitted elsewhere. Manuscripts should be prepared in accordance with the requirements specified as given in detail in the section of “Information for Authors”. The submission of the manuscript to the Journal is not a condition for acceptance; articles are accepted or rejected on merit alone. All rights reserved.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信